---
title: "Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286564149.md"
description: "Oppenheimer's Jeff Jones has reiterated a Buy rating on Corvus Pharmaceuticals (CRVS) with a price target of $33.00. Jones, a 5-star analyst, has an average return of 20.6% and a 43.35% success rate. Barclays also maintains a Buy rating with a $28.00 price target."
datetime: "2026-05-15T12:02:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286564149.md)
  - [en](https://longbridge.com/en/news/286564149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286564149.md)
---

# Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Corvus Pharmaceuticals, with a price target of $33.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Jones is a 5-star analyst with an average return of 20.6% and a 43.35% success rate. Jones covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Whitehawk Therapeutics, and Alumis Inc..

In a report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.

### Related Stocks

- [CRVS.US](https://longbridge.com/en/quote/CRVS.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)
- [WHWK.US](https://longbridge.com/en/quote/WHWK.US.md)
- [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)